Intellia Therapeutics Opens New Headquarters As Company Continues To Advance CRISPR/Cas9 Platform And Pipeline

- Positions Intellia for R&D growth and progress toward clinical studies - - Accommodates hiring plans to support pipeline of CRISPR/Cas9 based therapeutics -

CAMBRIDGE, Mass., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced the move to its new laboratory facilities at 40 Erie Street, in Cambridge. In recognition of Intellia's leadership in genome editing, Intellia CEO and Founder Nessan Bermingham, Ph.D., President and CEO of the Massachusetts Life Sciences Center Travis McCready, and President and CEO of MassBio Bob Coughlin, will inaugurate the new facility today at an evening ribbon cutting ceremony.

"The field of genome editing is rapidly evolving and our work to develop therapies for patients requires that we have the infrastructure necessary for R&D growth and prepare for preclinical studies and clinical trials," said Nessan Bermingham, Ph.D., Chief Executive Officer and Founder, Intellia Therapeutics. "To reach our goals, we continue to recruit top talent and ensure our quality workforce has the appropriate facilities and tools necessary to translate CRISPR/Cas9 into life-transforming products."

"This new facility allows Intellia to further advance our scientific programs and to continue to leverage our Massachusetts location alongside leading biotech research and academic institutions," Dr. Bermingham added.

About Intellia's New HeadquartersThe new Intellia headquarters was specifically designed to accommodate the Company's growing R&D, operations teams and administrative staff . Additionally, Intellia will maintain operations at its current facility at 130 Brookline Street in Cambridge. The new facility will increase Intellia's total laboratory and office space from the current 15,000 sq. ft. to more than 80,000 sq. ft. and will allow the company to double its team to more than 200 employees.

"Intellia Therapeutics' new headquarters is a testament to the potential of the company and the promise their transformative gene therapy represents to patients and their families living with severe and life-threatening diseases," said Governor Charlie Baker. "The innovations coming out of Massachusetts have a dramatic impact across the global life sciences sector, and we look forward to Intellia Therapeutics' continued growth and contributions to this field."

If you liked this article you might like

Intellia Therapeutics Is Worth Trading Right Now

Biotech Movers: Second Quarter Results, Increased Outlook Send Horizon Pharma Shares Higher

Biotech Movers Trading Positive Ahead of Market's Open

Allergan, Editas Sign Gene-Editing Pact for Rare Eye Diseases

Biotech Premarket Movers: Sucampo, Intellia, Cytokinetics